论文部分内容阅读
目的 探讨 期食管癌术后辅助化疗的方案。方法 2 0 0 1年 1月至 2 0 0 2年 9月 36例 期食管癌术后以健择联合顺铂方案辅助化疗 ,观察其对 1年生存率、局部复发及远处转移的影响 ,并按 WHO毒性反应分级标准评价毒副反应。结果 36例 1年生存率 84 % ,同期 期食管癌单纯手术 1年生存率 6 0 .6 % ,有显著差异 (P<0 .0 5 ) ;2例吻合口复发癌及 6例远处转移的平均时间为 9.5月及 12 .7月 ;毒副反应以血液系统及消化系统毒性为主 ,耐受性良好。结论 健择联合顺铂方案在 期食管癌术后辅助化疗方面值得进一步研究。
Objective To investigate the postoperative adjuvant chemotherapy regimen of esophageal cancer. Methods From January 2001 to September 2002 36 cases of esophageal cancer after esophageal cancer chemotherapy combined with cisplatin adjuvant chemotherapy to observe its 1-year survival rate, local recurrence and distant metastasis, Toxicity and classification according to WHO evaluation of toxic and side effects. Results One-year survival rate was 84% in 36 cases and single-year survival rate was 60.6% in simple esophageal cancer patients in the same period (P <0.05); 2 cases of anastomotic recurrence and 6 cases of distant metastasis The average time was 9.5 months and 12.7 months; toxic side effects of the blood system and digestive system toxicity, well tolerated. Conclusions Gemcitabine plus cisplatin is worth further research in the postoperative adjuvant chemotherapy of esophageal cancer.